![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Mayo Clinic National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00118092 |
RATIONALE: Drugs used in chemotherapy, such as 17-AAG, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well 17-AAG works in treating patients with metastatic prostate cancer that did not respond to previous hormone therapy.
Condition | Intervention | Phase |
Prostate Cancer |
Drug: tanespimycin |
Phase II |
MedlinePlus related topics: | Cancer Prostate Cancer |
ChemIDplus related topics: | IPI-504 17-(Allylamino)-17-demethoxygeldanamycin |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) In Patients With Hormone-Refractory Metastatic Prostate Cancer |
Study Start Date: | August 2005 |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 2-6 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses of treatment beyond documentation of CR.
After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 16-28 patients will be accrued for this study within 20 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma of the prostate
Measurable or evaluable disease
Objective disease progression OR rising PSA despite receiving androgen deprivation therapy and undergoing antiandrogen withdrawal
Must be castrate (testosterone < 50 ng/mL)
No known brain metastases requiring active therapy
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
No concurrent warfarin for anticoagulation
United States, Arizona | |||||
Mayo Clinic Scottsdale | |||||
Scottsdale, Arizona, United States, 85259 | |||||
United States, District of Columbia | |||||
Howard University Cancer Center at Howard University Hospital | |||||
Washington, District of Columbia, United States, 20060 | |||||
United States, Florida | |||||
Mayo Clinic - Jacksonville | |||||
Jacksonville, Florida, United States, 32224 | |||||
United States, Maryland | |||||
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |||||
Baltimore, Maryland, United States, 21231-2410 | |||||
United States, Michigan | |||||
Barbara Ann Karmanos Cancer Institute | |||||
Detroit, Michigan, United States, 48201-1379 | |||||
United States, Minnesota | |||||
Mayo Clinic Cancer Center | |||||
Rochester, Minnesota, United States, 55905 | |||||
United States, Missouri | |||||
Siteman Cancer Center at Barnes-Jewish Hospital | |||||
Saint Louis, Missouri, United States, 63110 | |||||
United States, Wisconsin | |||||
University of Wisconsin Comprehensive Cancer Center | |||||
Madison, Wisconsin, United States, 53792-6164 |
Mayo Clinic |
National Cancer Institute (NCI) |
Study Chair: | Elisabeth I. Heath, MD | Barbara Ann Karmanos Cancer Institute |
Clinical trial summary from the National Cancer Institute's PDQ® database 
![]()   |
Study ID Numbers: | CDR0000433492, MAYO-MC0453, NCI-6651 |
First Received: | July 8, 2005 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00118092 |
Health Authority: | United States: Federal Government |
|
|
|
|
![]() |